Kevin Sidow has been President and Chief Executive Officer for Moximed, Inc since 2004. Prior to this he was President and CEO for St. Francis Medical Technologies, Inc., a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. The Company raised a total of $28 million in venture capital. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon, Inc. Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, he oversaw the global orthopaedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopaedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion.
Justin Saliman, M.D.
Founder and Chief Medical Officer, Director
Dr. Justin Saliman practices orthopaedic surgery with a sports focus at Cedars-Sinai Hospital in Los Angeles. He founded and ran the incubator Revolutionary Surgical Device, LLC in late 2007 which went on to create SuturePro Technologies, LLC and Advanced Meniscus Technologies, LLC in 2009. These companies were merged in 2010 to form Ceterix Orthopaedics. Justin completed medical school at the University of Colorado School of Medicine in his hometown of Denver. He completed his residency in orthopaedic surgery at St. Lukes – Roosevelt Hospital center of Columbia University in New York City and a sports fellowship at Stanford University in Palo Alto.
Peter Bisgaard is a Partner in the San Francisco office of Novo Ventures (US) Inc. From 2001-2009, Peter was employed with Novo A/S as a partner in Novo Ventures. Prior to joining Novo A/S, he was with McKinsey & Co. as a general consultant and as a specialist focused on strategy development, mergers, acquisitions and alliances in various industries. Peter is the co-author of ‘Growth by Mergers & Acquisitions’ published by Børsens Forlag, 2004. He is also a member of the board of directors of Alder Biopharmaceuticals Inc., Asante Solutions Inc., HTG Molecular Diagnostics Inc., Otonomy Inc. and Thesan Pharmaceuticals Inc., and has been a board member of several EU and US companies. Peter obtained an MSc in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in Mathematical Modeling in Economics by the European Consortium for Mathematics in the Industry.
Mark S. Colella has over 19 years of venture capital and operating experience in life science, medical device and healthcare companies. Mark joined Stamos Capital Partners in 2015 as Managing Director, Private Equity, leading the private capital investment team. Previously a Principal, Mark is now an Advisor to 5AM Ventures, where he has held board and advisory roles with a number of public and private companies. In addition to Ceterix, Mark serves as a Director to Viveve (VIVMF), a women’s health medical device company. Mark was head of marketing for BÂRRX Medical, a medical device company sold to Covidien for $413 million, and he held management roles with Stryker, focused on orthopedics, laparoscopy, urology, gynecology, and minimally invasive general surgery. He spent four years on the founding team and as an Executive Director managing healthcare facilities with Primrose Alzheimer’s Living, an early-stage healthcare service start-up company, and one year working as an analyst for Versant Ventures, a life science venture capital firm. Mark holds a B.S. in Biology from Williams College and earned his M.B.A. from Northwestern University, the Kellogg School of Management, where he sits on the Advisory Board for the Innovation and New Ventures Office. Prior to Williams College, he spent two years at the United States Air Force Academy.
President and CEO, Director
John has 27 years of sales, marketing, and general management experience in medical devices. John started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx) and Ventus Medical. He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific) and LuMend (acquired by Johnson & Johnson). John holds B.A. degrees in Economics and Psychology from the University of California, Los Angeles and an M.B.A. from the UCLA Anderson Graduate School of Management.
Charles Warden has been an active medical device venture investor since 1992 and is currently Managing Director, Versant Ventures. Prior to joining Versant he was a general partner at Schroder Ventures Life Sciences (now SV Life Sciences) where he led SV’s medical device activity. Charles has served on numerous medical device company boards, including the following currently: AcuFocus, Celula, Concentric Medical, ForSight Vision4, Glumetrics, Halscion, Ocular Therapeutix and WaveTec. Since its inception, Charles has been actively involved with several medical device incubators including The Innovation Factory, ForSight Labs, and The Foundry.